Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer

This study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial. Based on the use of CDK4/6 inhibitors in endocrine-sensitive luminal-type (ER+/HER2-) breast cancer, it aims to explore the possibility of chemotherapy exemption in elderly patients (aged \>65 years) with lymph node-positive, HR+/HER2- breast cancer.

NCT Number	NCT07005557
Lead Sponsor	Fudan University
Conditions	Breast Cancer, Adjuvant Therapy
Enrollment	1,244 participants
Start Date	2025-06-15
Primary Completion	2030-05-15 (estimated)
Study Completion	2035-05-15 (estimated)
Updated on ClinicalTrials.gov	2025-06-05